12月5日，在Genesis 2023期間，美迪西與倫敦 MHA 聯(lián)合主辦Genesis Fringe Seminar。主題為：A UK-China Approach to Developing the Right Strategies for Early-stage Life Science Company Growth。

Epigenetic modification, like DNA methylation, plays a major role in the expression of genetic information. The DNA methyltransferases (DNMTs), maintain DNA methylation, is an attractive target for tu

Idiopathic pulmonary fibrosis is a chronic and lethal lung disease associated with fibroblast activation, myoblast proliferation and extracellular matrix deposition. SKLB-YTH-60 was developed through

The inhibition of HDACs will lead to compensated activation of a notorious cancer-related drug target, STAT3, in breast cancer through a cascade, which probably limits the anti-proliferation effect of

目前全球在研AOC的公司主要有：Avidity Biosciences、Dyne Therapeutics、Tallac Therapeutics、Denali Therapeutics等。

Immune checkpoint inhibition therapies have been used for multiple cancer research. H11-HLE is a tool molecule that allows the interrogation of the contribution of Fc in mediating immune checkpoint therapy. Half-life extended H11 (H11-HLE) induces potent

BioSeed 2023——The Early-Stage Life Sciences Investment Event 將于2023年1月23日在英國(guó)倫敦舉行。美迪西歐洲團(tuán)隊(duì)將全程出席此次大會(huì)。

BioForward 2022- The 'Roadmap for Growth' Life Sciences Event 將于2022年9月27日在英國(guó)舉行，美迪西歐洲團(tuán)隊(duì)將全程出席此次大會(huì)，歡迎到展位號(hào)22與我們現(xiàn)場(chǎng)洽談。

禮來(lái)公司下屬的研發(fā)集團(tuán)Loxo Oncology和Kumquat Biosciences聯(lián)合宣布，雙方達(dá)成獨(dú)家合作協(xié)議，將共同發(fā)現(xiàn)、開(kāi)發(fā)和商業(yè)化一系列引起腫瘤特異性免疫反應(yīng)的創(chuàng)新型小分子候選藥。作為合作伙伴，美迪西有幸見(jiàn)證了Kumquat的成長(zhǎng)。目前，美迪西約有50名科研人員為Kumquat提供化學(xué)FTE服務(wù)。美迪西憑可靈活調(diào)整的方案、可控的項(xiàng)目進(jìn)展、可定制的合成線路，正持續(xù)為Kumquat賦能。

緊跟新藥前沿，專注研發(fā)創(chuàng)新,讓我們來(lái)盤點(diǎn)一下最新醫(yī)藥行業(yè)動(dòng)態(tài)吧：北京五和博澳藥業(yè)有限公司桑枝總生物堿片（中藥5類申報(bào)的天然藥物）近期獲批上市，國(guó)內(nèi)首個(gè)可用于新冠急性肺損傷藥品也獲批上市；“封裝”細(xì)胞療法新銳B輪融資8030萬(wàn)美元，優(yōu)瑞科完成4500萬(wàn)美元E輪融資；海和生物獲得上海藥物所STING激活劑全球獨(dú)占許可，安渡生物與Altasciences達(dá)成戰(zhàn)略合作。

陳春麟博士在海南三亞參加“ ASIA LIFE SCIENCES CEO MEETING ORGANIZED BY ORBIMED”